← Back to Search

Opioid Partial Agonist

Buprenorphine extended-release injection for Opioid Use Disorder (FASTER-BUP Trial)

Phase 4
Recruiting
Led By M. Eugenia Socias, MD, MSc.
Research Sponsored by M. Eugenia Socias
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be above 19 years of age;
Be diagnosed with moderate or severe OUD as evidenced by their approval for treatment with XR-BUP (Sublocade);
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

FASTER-BUP Trial Summary

This study is evaluating whether extended-release injectable buprenorphine (XR-BUP) is a feasible and clinically useful treatment for opioid use disorder (OUD) among individuals at high-risk for overdose (OD).

Eligible Conditions
  • Opioid Use Disorder
  • Opioid Overdose

FASTER-BUP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

FASTER-BUP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of XR-BUP injections received
Proportion of treatment-engaged visits per participant
Secondary outcome measures
Percentage of opioid free weeks
Safety monitoring

FASTER-BUP Trial Design

1Treatment groups
Experimental Treatment
Group I: SublocadeExperimental Treatment1 Intervention
This consists of 2 once-monthly 300 mg followed by 4 once-monthly 100 mg subcutaneous injections.

Find a Location

Who is running the clinical trial?

M. Eugenia SociasLead Sponsor
1 Previous Clinical Trials
27 Total Patients Enrolled
BC Centre on Substance UseLead Sponsor
2 Previous Clinical Trials
218 Total Patients Enrolled
Indivior Inc.Industry Sponsor
53 Previous Clinical Trials
10,623 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
M. Eugenia Socias 2022. "Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04815590.
~17 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top